Cargando…

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4

OBJECTIVE: To identify the power of tumor markers for predicting ovarian cancer according to menopausal status. METHODS: The medical records of 876 women with ovarian cysts were retrospectively reviewed. Cancer antigen 125 (CA 125), human epididymis protein 4 (HE4), and Risk of Ovarian Malignancy Al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kyung Hee, Park, Noh Hyun, Kim, Jin Ju, Kim, Sunmie, Kim, Hee Seung, Lee, Maria, Song, Yong Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779620/ https://www.ncbi.nlm.nih.gov/pubmed/31576682 http://dx.doi.org/10.3802/jgo.2019.30.e83

Ejemplares similares

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report
por: Khodaverdi, Sepideh, et al.
Publicado: (2018)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
por: Abdalla, Nabil, et al.
Publicado: (2018)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
por: Shin, Kyung-Hwa, et al.
Publicado: (2020)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer
por: Abdalla, Nabil, et al.
Publicado: (2016)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses
por: Terlikowska, Katarzyna M., et al.
Publicado: (2016)

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial
por: Dochez, Vincent, et al.
Publicado: (2019)

Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms
por: Song, Zixuan, et al.
Publicado: (2023)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
por: Hamed, Elham O, et al.
Publicado: (2013)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer
por: Abdalla, Nabil, et al.
Publicado: (2017)

Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer
por: Lee, Sun Seong, et al.
Publicado: (2021)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
por: Rong, Yan, et al.
Publicado: (2021)

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
por: Wan, Qiuhua, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses
por: Song, Liyun, et al.
Publicado: (2023)

Peri and post-menopausal women with complex adnexal masses, ascites, and raised CA-125: Is it ovarian cancer or tuberculosis?
por: Bagga, Rashmi, et al.
Publicado: (2016)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
por: Shittu, Khadijah Adebisi, et al.
Publicado: (2023)

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
por: Kim, Hee Seung, et al.
Publicado: (2016)

Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings
por: Wilailak, Sarikapan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o4qt9u6mjuavaifmcqui29s5tk